GERN Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds Geron Corporation (GERN) Shareholders of Securities Fraud Class Action Lawsuit Deadline

Core Viewpoint - Securities class action lawsuits have been filed against Geron Corporation for allegedly misleading investors regarding its revenue outlook and product performance during the specified class period [1][3]. Group 1: Allegations Against Geron Corporation - Defendants allegedly created a false impression of reliable information regarding Geron's revenue outlook and growth potential while downplaying risks from seasonality and macroeconomic factors [3]. - Reports on the launch success and growth potential of Geron's primary product, RYTELO, were claimed to be overly optimistic and did not reflect the reality of market conditions, competition, and patient initiation challenges [3]. - RYTELO reportedly lacked market awareness, hindering Geron's ability to meet the significant unmet need for the drug, particularly among first-line patients and those outside academic settings [3]. - Statements made by the defendants regarding the company's business and prospects were alleged to be materially false and misleading [3]. Group 2: Legal Process for Investors - Geron investors have until May 12, 2025, to seek appointment as lead plaintiff representatives in the class action through Kessler Topaz Meltzer & Check, LLP or other counsel [4]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the proposed class [4]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [4].